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Background: Kidney transplantation (KT) is the treatment of choice for end-stage
renal disease patients. The spouse is a major donor in living KT. Clinical outcomes
of spousal donor KT are not inferior to those of living related donor KT. In this study,
we compared clinical outcomes between ABO-compatible (ABOc) and ABO-
incompatible (ABOi) spousal donor KTs.
Methods: Thirty-two cases of spousal donor KT performed from January 2011 to
August 2013 were analyzed retrospectively. Twenty-one ABOc KTs and 11 ABOi KTs
were performed. We investigated patient survival, graft survival, acute rejection,
graft function, and complications.
Results: During follow-up, patient and graft survival rates were 100% in both
groups. There were no signiﬁcant differences in the incidence of delayed graft
function, acute rejection, and the change in graft function between the 2 groups.
Medical and surgical complications were not signiﬁcantly different between the
groups.
Conclusion: The clinical outcomes of ABOc and ABOi spousal donor KTs were
equivalent. In ABOi KT, an emotionally motivated spousal donor KT may be a good
alternative to the problem of the absolute shortage of kidney donations.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Kidney transplantation (KT) is the treatment of choice for
end-stage renal disease (ESRD) patients [1]. With the global
increase in ESRD patients with chronic diseases such as dia-
betes mellitus, hypertension, and chronic glomerulonephritis
[2], the need for KT increases annually. However, the shortagenal Medicine, Keimyung
iversity Kidney Institute,
ty of Nephrology. Published b
/4.0/).of kidney donors is still a critical problem. In Korea, the number
of ESRD patients on the waiting list was 14,448 as of December
2013, and only 1,759 patients received KT during 2013 [3]. To
solve this problem, living unrelated donor KT, in addition to
living related donor (LRD) KT, deceased donor KT, and even
extended criteria donor KT are currently being performed [4].
Especially, to compensate for the shortage of kidney donations
in Korea, ABO-incompatible (ABOi) KT was ﬁrst performed in
2007 [5]. The development of immunosuppressive agents and
pretreatment methods, such as plasmapheresis, and the use of
intravenous immunoglobulin and rituximab have made ABOi
KT possible [6]. Several studies reported that outcomes of ABOiy Elsevier. This is an open access article under the CC BY-NC-ND license
Figure 1. Flow chart of selection for study population.
ABOc, ABO compatible; ABOi, ABO incompatible; KT, kidney trans-
plantation; LDKT, living donor kidney transplantation; LRD, living related
donor.
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[7e9]. Along with the trend toward a smaller family size
comprising spouses and children in contemporary society, the
rate of spousal donor KT has increased. Because a spousal donor
currently accounts for most ABOi KT cases, the spouse is the
most important donor in living KT [10e12]. It is known that
clinical outcomes of ABOc spousal donor KT are not different
from those of ABOc LRD KT [10].
In this study, we compared the clinical outcomes of ABOc KT
with those of ABOi KT with a spousal donor.
Methods
Patient characteristics
We retrospectively analyzed the medical records of 143 KTs
performed at Dongsan Medical Center, Keimyung University
School of Medicine, between January 2011 and August 2013.
This study was approved by the Institutional Review Board of
Keimyung University School of Medicine (2015-07-053).
Immunosuppression protocols
We performed KT when the removal of donor-speciﬁc anti-
human leukocyte antigen (HLA) antibodies was observed with
serial anti-human globulin complement-dependent cytotox-
icity (AHG-CDC) cross-matching. Basiliximab (20 mg on Days
0 and 4, Simulect; Novartis, Basel, Switzerland) was adminis-
tered for induction of immunosuppression for all recipients of
ABOc and ABOi KTs, except for HLAeidentical patients. The
maintenance immunosuppressive regimen consisted of tacro-
limus (Prograf; Astellas Pharma Inc., Toyama, Japan), cortico-
steroid, and mycophenolate mofetil (MMF, CellCept; Hoffmann-
La Roche Inc., Nutley, NJ, USA).
In ABOc KT recipients, tacrolimus (0.05 mg/kg twice a day),
corticosteroid (15 mg twice a day), and MMF (750 mg twice a
day for weight < 60 kg or 1,000 mg twice a day for weight
 60 kg) were administered on pretransplant Day 2. A trough
level of tacrolimus was maintained at 5e10 ng/mL for a month
after transplantation and 3e8 ng/mL thereafter. Methylpred-
nisolone was administered at a dose of 500 mg twice a day on
the day of the operation and 50 mg twice a day on post-
transplant Day 1. Prednisolone (30 mg/d) was administered
starting on post-transplant Day 2 for 2 weeks and was tapered
to a dose of 10 mg/d by 3 months after transplantation.
In ABOi KT recipients, we excluded the candidate when the
initial titer of anti-A/B antibody was greater than 1:256. A single
dose of rituximab (200 mg/m2; Roche Pharma AG, Reinach,
Switzerland) was administered 2 weeks before KT. MMF was
administered 12 days before KT (750 mg twice a day for weight
< 60 kg or 1,000 mg twice a day for weight 60 kg). Tacrolimus
(0.05 mg/kg twice a day) and prednisolone (15 mg twice a day)
were administered 10 days before KT. A trough level of tacroli-
mus was maintained as for ABOc KT. All ABOi KT recipients un-
derwent double-ﬁltration plasmapheresis (1.5 plasma volumes
exchanged with 5% albumin) every other day, with a ﬁnal pre-
operative totalplasmaexchange (withABblood type fresh frozen
plasma), until antieblood-type antibody titer was less than or
equal to 1:8 at the time of KT. After individual plasmapheresis,
intravenous immunoglobulin (100 mg/kg) was administered.
All patients received preventive ganciclovir (2.5 mg/kg twice
a day) against cytomegaloviral (CMV) infection for 14 days afterKT, trimethoprimesulfamethoxazole (80 mg/400 mg twice a
day) against Pneumocystis jiroveci pneumonia, and oral ﬂucon-
azole (5 mL once a day) against fungal infection for 6 months.
In this study, we investigated patient and graft survival
rates, delayed graft function (DGF), graft function as the change
in estimated glomerular ﬁltration rate (eGFR), acute rejection,
andmedical and surgical complications after ABOc and ABOi KT
with a spousal donor during the follow-up period.
Demographic and clinical data
Baseline characteristics of the study populations included
donor and recipient age at KT, donor-to-recipient relationship,
cause of ESRD, comorbidity, type and duration of renal
replacement therapy (RRT), history of KT, number of HLA
mismatches, and primary immunosuppressant.
Statistical analyses
We analyzed data using the Student's t test for continuous
variables and chi-square test for categorical variables. Contin-
uous variables are presented as the means ± standard deviation,
and categorical variables are expressed as numbers and per-
centages. Analyses of patient and graft survival were performed
using the KaplaneMeier method with log-rank test. Nonpara-
metric tests for comparisons between the 2 groups of nonnormal
distribution were performed using the ManneWhitney test. A P
values < 0.05 were considered statistically signiﬁcant. Statistical
analysis was performed using SPSS (version 18.0, SPSS Inc.,
Chicago, IL, USA) statistical software package.
Results
Baseline characteristics of the ABOc and ABOi groups in
spousal donor KT
Among 32 spousal donor KTs, 21 kidneys (31.3%) were from
ABOc donors and 11 (57.9%) from ABOi donors. There were 12
(57.1%) wife-to-husband and 9 (42.9%) husband-to-wife ABOc
KTs, and 9 (81.8%) and 2 (18.2%) ABOi KTs, respectively (Fig. 1).
All the wives as recipients had a history of two pregnancies
except 1 person. The mean ages of donors and recipients in
ABOc KT were older than those in ABOi KT, but there were no
Kidney Res Clin Pract 35 (2016) 50e5452signiﬁcant differences between the groups (Table 1). Among
the causes of ESRD, chronic glomerulonephritis was the most
common cause in both ABOc KT [15 (71.4%)] and ABOi KT [8
(72.7%)], but there were no signiﬁcant differences between
the groups. The most common type of RRT before KT in ABOc
and ABOi patients was hemodialysis [14 (66.7%) and 8 (72.7%),
respectively]. The mean numbers of HLA mismatches in ABOc
and ABOi KTs were 3.4 ± 1.5 and 4.4 ± 0.8, respectively, and the
difference was signiﬁcant (P ¼ 0.026). The primary immuno-
suppressive agent in all patients was tacrolimus (21 in ABOc
KT), with cyclosporine used in only 1 ABOi KT patient.Figure 2. Changes in anti-A/B antibody titer in ABOi spousal donor KT.
ABOi, ABO incompatible; KT, kidney transplantation.Changes in anti-A/B antibody titer and distribution of ABO
type of ABOi spousal donor KT
Changes in anti-A/B antibody titer in ABOi spousal donor KT
are shown in Fig. 2. The ABO type of ABOi spousal donor KT
patients is shown in Fig. 3A. The range of initial anti-A/B anti-
bodies was from 1:2 to 1:128 (Fig. 3B). The median titer of anti-
A/B antibody was 1:32, 1:4, and 1:2 initially, at the time of KT,
and 1 week after KT, respectively. The median number of
plasmapheresis treatments was 5 (0e6). All patients satisﬁed
the criterion of antieblood-type antibody titer less than or
equal to 1:8 at the time of KT, and the titers remained less than
or equal to 1:8 until 1 month after KT.Patient and graft survival rates, DGF, renal allograft function,
and acute rejection
During the follow-up period, overall patient and graft sur-
vival rates were 100% in both groups (Table 2). In ABOc KT, 1Table 1. Baseline characteristics of the ABOc and ABOi groups in
spousal donor KT
Variable ABOc (n ¼ 21) ABOi (n ¼ 11) P
Recipient age (y) 50.9 ± 8.4 49.0 ± 6.5 0.508*
Donor age (y) 49.3 ± 7.9 47.6 ± 8.5 0.572*
Donor-to-recipient relationship 0.248y
Wife to husband 12 (57.1) 9 (81.8)
Husband to wife 9 (42.9) 2 (18.2)
Cause of ESRD 0.863y
Diabetes mellitus 4 (19.0) 2 (18.2)
Hypertension 1 (4.8) 1 (9.1)
Chronic GN 15 (71.4) 8 (72.7)
ADPKD 1 (4.8) 0 (0)
Comorbidity
Diabetes mellitus 6 (28.6) 3 (27.3) 1.000y
Hypertension 19 (90.5) 8 (72.7) 0.310y
Cardiovascular disease 3 (14.3) 1 (9.1) 1.000y
Type of RRT 1.000y
Hemodialysis 14 (66.7) 8 (72.7)
Peritoneal dialysis 4 (19.0) 2 (18.2)
None 3 (14.3) 1 (9.1)
Duration of RRT (mo) 21.4 ± 39.7 38.5 ± 48.8 0.295*
First KT 20 (95.2) 10 (90.9) 1.000y
HLA mismatch 3.4 ± 1.5 4.4 ± 0.8 0.026*
Main immunosuppressant 0.344y
Tacrolimus 21 (100) 10 (90.9)
Cyclosporine 0 (0) 1 (9.1)
Data are presented as mean ± SD or number (%).
*Student's t test.
yChi-square test.
ABOc, ABO compatible; ABOi, ABO incompatible; ADPKD, autosomal
dominant polycystic kidney disease; ESRD, end-stage renal disease; GN,
glomerulonephritis; KT, kidney transplantation; RRT, renal replacement
therapy; SD, standard deviation.(4.8%) DGF occurred. In ABOi KT, 1 (9.1%) acute antibody-
mediated rejection (AAMR) occurred and was veriﬁed by
renal biopsy. Panel-reactive antibody Class I positivity was 0%
and Class II was 80%, but HLA donor-speciﬁc antibodies (DSAs)
were not tested for. AAMR occurred 9 months after KT because
of the persistent low tacrolimus level after CMV gastritis. One
week, 1 month, 3 months, 6 months, and 1 year after KT, eGFRs
were 79.47 ± 31.73, 70.24 ± 17.41, 62.73 ± 9.78, 64.90 ± 15.53,
and 66.01 ± 20.85, respectively, for ABOc KT, and 93.32 ± 28.50,
82.46 ± 21.18, 72.01 ± 19.25, 66.44 ± 16.93, and 67.22 ± 23.20
for ABOi KT, but there were no signiﬁcant differences between
the groups.Figure 3. The distribution of (A) ABO type and (B) initial anti-A/B
antibody titer in ABOi spousal donor KT.
ABOi, ABO incompatible; KT, kidney transplantation.
Table 2. Patient and graft survival and post-transplant renal function
in spousal donor KT
Variable ABO compatible
(n ¼ 21)
ABO incompatible
(n ¼ 11)
P
Patient and graft survival
Patient survival 21 (100) 11 (100) 1.000*
Graft loss 0 (0) 0 (0)
Delayed graft
function
1 (4.8) 0 (0) 1.000*
Acute rejection
episode
0 (0) 1 (9.1) 0.341*
Follow-up
duration (mo)
15.2 ± 7.7 14.5 ± 8.0 0.798y
Graft function
eGFR (MDRD) (mL/min/1.73 m2)
1 wk after KT 79.47 ± 31.73 93.32 ± 28.50 0.235y
1 mo after KT 70.24 ± 17.41 82.46 ± 21.18 0.090y
3 mo after KT 62.73 ± 9.78 72.01 ± 19.25 0.158y
6 mo after KT 64.90 ± 15.53 66.44 ± 16.93 0.797y
1 y after KT 66.01 ± 20.85 67.22 ± 23.20 0.885y
Data are presented as mean ± SD or number (%).
*Chi-square test.
yStudent's t test.
eGFR, estimated glomerular ﬁltration rate; KT, kidney transplantation;
MDRD, Modiﬁcation of Diet in Renal Disease.
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CMV infection occurred in 4 (19%) ABOc KT and 2 (18.2%)
ABOi KT patients (Table 3). Other viral, bacterial, and Candida
infections occurred in 2 (9.5%), none, and 1 (4.8%), and 2
(18.2%), 1 (9.1%), and none, in ABOc KT and ABOi KT patients,
respectively. Those were varicella-zoster virus, herpes zoster
virus, and herpes simplex virus infections. There were no sig-
niﬁcant differences between the groups. New-onset diabetes
after transplantation occurred in 4 ABOc (19%) and 4 ABOi pa-
tients (36.4%), but this difference was not statistically signiﬁ-
cant. Hyperlipidemia occurred in 7 ABOc (33.3%) and 2 ABOi
patients (18.2%), but there was no signiﬁcant difference. Sur-
gical complications such as bleeding, lymphocele, and urinoma
occurred in 4 ABOc (19%) and 3 ABOi patients (27.3%), but this
difference was not statistically signiﬁcant.
Discussion
In this study, we demonstrated that KT from an ABOi spousal
donor was equivalent to that from an ABOc spousal donor in
terms of patient and graft survival, allograft function, and acute
rejection. These results are in the extension of the previousTable 3. Complications in spousal donor KT
Variable ABO compatible
(n ¼ 21)
ABO incompatible
(n ¼ 11)
P
Infectious complications
CMV infection 4 (19.0) 2 (18.2) 0.954*
Other viral infection 2 (9.5) 2 (18.2) 0.498*
Bacterial infection 0 1 (9.1) 0.341*
Candida infection 1 (4.8) 0 0.478*
NODAT 4 (19.0) 4 (36.4) 0.298*
Hyperlipidemia 7 (33.3) 2 (18.2) 0.441*
Surgical complications 4 (19.0) 3 (27.3) 0.607*
Data are presented as number (%).
*Chi-square test.
CMV, cytomegalovirus; KT, kidney transplantation; NODAT, new-onset
diabetes after transplantation.studies such as the comparison of spousal donor KT and LRD KT
in ABOi KT [13] or that of ABOc KT and ABOi KT [14].
Several studies reported that spousal donor KT showed
lower HLA typing compatibility than deceased donor KT [10],
but patient and graft survival rates were higher. Although the
age of donors and recipients in spousal donor KT was greater
than that in LRD KT, the results of transplantation were not
signiﬁcantly different. Several studies demonstrated that the
incidence of infection and bleeding was higher in ABOi KT than
ABOc KT because of the desensitization process before KT [15],
but there were no signiﬁcant differences in patient and graft
survival between the groups.
In our study, recipient age, donor age, cause of ESRD, co-
morbidity, RRT type, duration of RRT, and the frequency of KT
were not signiﬁcantly different between ABOc and ABOi KT
with a spousal donor. It is known that HLA mismatching is an
important factor affecting graft survival in KT recipients [16],
but the development of immunosuppressive agents has
reduced the inﬂuence of HLA mismatching on graft survival in
KT recipients. Several studies showed that spousal donor KT
had low HLA matching compared with cadaveric donor KT but
had a higher graft survival rate [17]. In our study, HLA mis-
matching was signiﬁcantly higher in ABOi than in ABOc KT but
was not signiﬁcantly associated with the graft survival rate.
However, longer follow-up is needed.
There were no signiﬁcant differences in patient and graft
survival between ABOc and ABOi KTs. In ABOc KT, 1 (4.8%) DGF
occurred. Blood pressure decreased with the decrease in the
hemoglobin level a day after KT, and allograft biopsy showed
acute tubular necrosis. ABOi spousal donor KT did not show a
higher frequency of DGF compared to ABOc KT. This was
consistent with several studies showing that spousal donor KT
did not have a higher rate of DGF compared with LRD and
cadaveric KTs and that ABOi KT did not have a higher rate of
DGF compared with ABOc KT. On 1 week, 1 month, 3 months, 6
months, and 1 year after KT, the mean eGFR was not signiﬁ-
cantly different between ABOc and ABOi KT.
It is known that there is no difference in the incidence of
acute rejection between LRD and spousal donor ABOc KTs
[18]. However, LRD and spousal donor ABOi KTs had a higher
incidence of AAMR, especially in the ﬁrst 2 weeks after KT,
and was associated with the change in anti-A/B antibody titer
after KT [19e21]. In our study, 1 person had AAMR in ABOi
KT. At that time, anti-A/B antibody titer showed no interval
change after KT. It could be surmised that the cause of AAMR
was HLA DSA, not anti-A/B antibody. The results of our study
differed from others reporting that the major antibody for
AAMR in ABOi KT was either anti-A/B antibody or anti-HLA
antibody, but the latter had greater inﬂuence on graft
outcome [5].
The medical and surgical complications in spousal donor KT
are reported in Table 3. ABOi KT had a higher incidence of viral
infection because of intensiﬁed immunosuppression and
bleeding complications after pretransplantation treatment
[21]. Although intensive desensitization for anti-A/B antibody
in ABOi KT was performed, there were no signiﬁcant differ-
ences in the prevalence of CMV and other infections between
ABOc and ABOi KTs. There were also no signiﬁcant differences
in metabolic complications such as new-onset diabetes after
transplantation and hyperlipidemia between ABOc and ABOi
KTs. ABOi KT tended to have more frequent surgical compli-
cations such as lymphocele or hematoma than ABOc KT, but the
Kidney Res Clin Pract 35 (2016) 50e5454difference was not signiﬁcant. This was not correlated with the
frequency of plasmapheresis.
This study has several limitations. First, our study is retro-
spective, and the number of patients is limited. Therefore, it is
possible that unrecognized selection bias may affect the results.
Second, because the follow-up period is short, there are limi-
tations in evaluating the patient and graft survival rates. Third,
there was no treatment for pretransplant desensitization for
patients with a high panel-reactive antibody level because of
lack of information about DSA. In ABOi KT, only anti-A/B anti-
body titer was conﬁrmed, and ABOi KT in highly sensitized
patients was not considered. Finally, in our study, ABO titer was
lower than that in the other studies, so it could not be the
representative of current ABOi transplant, and it was the reason
for lower incidence of postoperative complications.
In conclusion, KT from an ABOi spousal donor was equiva-
lent to that from an ABOc spousal donor in terms of patient and
graft survival, allograft function, and acute rejection in our
study. As nuclear families andmarriage age are both increasing,
it will be difﬁcult to ﬁnd suitable LRDs and living unrelated KT
donors. A genetically incompatible but emotionally motivated
spousal donor can be a good alternative to solve the absolute
shortage of kidney donations. Spousal donors already account
for most ABOi KT currently performed and could be an
important source of donor kidneys for both ABOc and ABOi KTs.Conﬂicts of interest
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